Dr. Jakubowiak on Phase I Daratumumab Regimens in Newly Diagnosed Multiple Myeloma

Andrzej Jakubowiak, MD, PhD, professor of medicine, director, Myeloma Program, The University of Chicago Medicine, discusses a phase I study of daratumumab (Darzalex) in combination with carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (KRd) in patients with newly diagnosed multiple myeloma.

Investigators believe progress is being made with some other novel regimens in multiple myeloma and able to get several patients to minimal residual disease (MRD)-negativity, Jakubowiak says. KRd, as a triplet, has emerged as an active regimen that has performed better against other therapies, he says. Additionally, KRd can be further improved by implementing transplant.

Rather than transplant, researchers sought to combine KRd with daratumumab, defined by Jakubowiak as one of the most promising agents in the field. Thus far, regimens explored with daratumumab have shown great promise, leading to the rationale for this study.